US › Healthcare

Adial Pharmaceuticals Inc (ADIL)

US · Healthcare · Biotechnology

$5.21-0.57%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-52.0M

EPS

$-11.25

EPS estimate

$-0.91

EPS came in at -11.25 against a street estimate of -0.91 — a miss of 1136.3%.

Key statistics

Market cap

$14.4M

Forward P/E

0.0

P/B

3.52

Book value

$-14.62

EPS (TTM)

$-17.71

52-week high

$10.75

52-week low

$1.31

50-day MA

$4.27

200-day MA

$3.68

Beta

1.39

Analyst view

Analysts rate Adial Pharmaceuticals Inc a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $8.33.

Shareholding

Insiders

7.08%

Institutions

29.85%

Largest institutional holders

Fund	Stake
Citadel Advisors Llc	1.13%
Geode Capital Management, LLC	0.92%
China Universal Asset Mgmt Co.Ltd	0.30%
Vanguard Fiduciary Trust Co	0.22%
Manchester Capital Management LLC	0.07%
Tower Research Capital LLC	0.05%
BlackRock Inc	0.04%
UBS Group AG	0.02%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Adial Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.